Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer

BACKGROUND: HER2-low has emerged as a new predictive biomarker in metastatic breast cancer. However, its prognostic value in early-stage carcinomas needs to be revisited. We aimed to evaluate the association of HER2-low carcinomas with PAM50 risk groups combined with clinicopathological variables in...

Descripción completa

Detalles Bibliográficos
Autores principales: Terán, Santiago, Alva, Manuel, Tolosa, Pablo, Rey-Cárdenas, Macarena, Madariaga, Ainhoa, Lema, Laura, Ruano, Yolanda, Manso, Luis, Ciruelos, Eva, Sánchez-Bayona, Rodrigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392598/
https://www.ncbi.nlm.nih.gov/pubmed/37481795
http://dx.doi.org/10.1016/j.breast.2023.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392598/
https://www.ncbi.nlm.nih.gov/pubmed/37481795
http://dx.doi.org/10.1016/j.breast.2023.07.009

Ejemplares similares